

# **Coeliac UK**

**Annual Report and Financial Statements for the year ended 31 December 2025**

---

**COELIAC UK**  
**(A Company Limited by Guarantee)**

**Registered Charity Number: 1048167**  
**Registered Company Number: 03068044**  
**Scottish Charity Number: SC039804**

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

<b>Contents</b>	<b>Page</b>
Legal and administrative information	3-4
Structure, Governance and Management	5-7
Report of the Board of Trustees	8-20
Independent Auditors' report	21-25
Consolidated statement of financial activities	26
Consolidated balance sheet	27
Consolidated statement of cash flows	28
Notes to the financial statements	29-45

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

The organisation is a charitable company limited by guarantee, incorporated on 14 June 1995 and registered as a UK Charity on 20 July 1995. Coeliac UK is the successor organisation to The Coeliac Society which was established in 1968.

The Charity is governed by its Articles of Association which set out its objects and powers.

The Articles provide for the Board to comprise of not more than twelve, nor fewer than three Trustees, of which one Trustee shall be nominated by the Health Advisory Council. A trustee shall hold office for a period of 3 years and shall then be subject to re-election and may be re-elected for a further term of 3 years after which they must retire as a Trustee but may be re-elected as a Trustee after an intervening period of at least 1 year. The trustees have all served for the full year unless otherwise stated.

### Board of Trustees

Lawrence Broadie  
Sarah Bull (appointed 14 June 2025)  
Anne Davis  
Kate Denham  
Chris Dilloway – Chair  
Aishah Farooq  
Nuala Gallagher (appointed 14 June 2025)  
Clive Hart (resigned 26 February 2026)  
Dr Anita Patel  
Dr Gerry Robins  
Miranda Sheffield  
Nicola Valmas

### Company Secretary

Ashley Bailey (resigned 20 February 2025)  
Sally Malthouse (appointed 20 February 2025)

### Chief Executive

Hilary Croft

### Company Number

**03068044**

### Charity Number

**1048167**

### Scottish Charity Number

**SC039804**

### Registered office address

Artisan  
Hillbottom  
High Wycombe  
Buckinghamshire  
HP12 4HJ

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### **Auditors**

Moore Kingston Smith LLP  
9 Appold Street  
London  
EC2A 2AP

### **Bankers**

HSBC Bank plc  
Oxford Circus Branch  
196 Oxford Street  
London  
W1D 1NT

Lloyds Bank plc  
21-31 White Hart Street  
High Wycombe  
Buckinghamshire  
HP11 2HL

### **Investment Manager**

Cazenove Capital  
1 London Wall Place  
London  
EC2Y 5AU

### **Solicitors**

Blaser Mills  
Park House  
40 Oxford Road  
High Wycombe  
Buckinghamshire  
HP11 2EE

# Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2025

---

## The Charity

### Structure, Governance and Management

Coeliac UK is a charitable company limited by guarantee, incorporated on 14 June 1995, and registered as a Charity on 20 July 1995 with the Charity Commission. It was also registered with the Office of the Scottish Charity Regulator in 2008.

The Charity's objectives, as set out in its Articles of Association, are:

- improving the wellbeing and outcomes of people affected by the Coeliac condition;
- increasing awareness and knowledge and improving the care and choice for those affected by the Coeliac condition; and
- promoting research into the nature, causes, alleviation, treatment and cure of the Coeliac condition.

#### Public Benefit

The Trustees, in exercising their powers and duties, have complied with their duty in Section 17 of the Charity Act 2011 to have due regard to the public benefit guidance published by the Charity Commission. In preparing the report and accounts, the Trustees complied with the requirements in that guidance to report on the significant activities and achievements of the Charity in 2025. They have reported in a way that both sets out the aims and strategies of the Charity and demonstrates how the aims and activities of the Charity were carried out for the public benefit.

#### Management and Staff

The Board of Trustees delegates the day-to-day management of the Charity to the Chief Executive who led a team of approximately 63 (54 full time equivalent) staff in 2025. Their work is supplemented at times of peak workload by a limited number of temporary staff. The staff work within the Delegation of Authority agreed by the Board. The staff agree an annual Business Plan with the Board prior to the beginning of the year and regularly report progress throughout the year and at each Board meeting.

The Board of Trustees appoints a People Committee to oversee the setting of pay and remuneration for senior management and the entire organisation. Their remit is to regularly review and agree performance review arrangements; agree remuneration policies including terms, conditions and benefits; consider recommendations for individual pay on the basis of individual appraisals and to consider the Charity's human resource strategy. The committee comprises the Chair of the Board of Trustees and at least two other Trustees.

#### The Board of Trustees

The Board of Trustees lead the Charity in setting its strategic direction and agreeing strategic objectives and plans to deliver the Charity's aims. The Board monitors and evaluates the progress of the Charity to ensure it achieves those objectives and plans.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

The expertise within the Board is substantial, wide-ranging and importantly complementary. Trustees include director-level individuals from a wide range of relevant disciplines including finance, HR, marketing, and healthcare. All Trustees are volunteers committing many hours to the work of the Charity.

The Board meets regularly and no less than 4 times per annum.

To support effective governance, a number of committees have been established to oversee, advise, and make recommendations to the Board of Trustees on specific areas of the organisation's activities. Some of these committees include specialists and other advisers who are not trustees; such members are recruited through the same process as trustees and provide additional focus and expertise on key matters.

The main committees are the Audit, Investment and Risk Committee, the People Committee, the Engagement Committee, the Executive Action Committee, the Health Advisory Council (HAC), the Food Standards Committee (FSC), and the Research Strategy Board (RSB).

Each committee has its own terms of reference, which set out its duties, responsibilities, and delegated authorities. These are reviewed on a regular basis.

### Meeting Protocol

The Boards and committees continued to use a combination of face-to-face meetings, video calls and teleconferences during the year to review plans and activities of the Charity and ensure the cost effectiveness of their operations.

### Recruiting and Supporting Trustees

The Board of Trustees regularly undertakes an audit to identify current and emerging skills gaps. Vacant roles are advertised widely both in the Charity's communications to members and on recruitment websites open to all. The selection process comprises shortlisting based on CVs and supporting statements, followed by an interview panel for shortlisted candidates. Following appointment, new Trustees are provided with induction packs, formal training as required for the role, and sessions spent with key staff.

### Group Structure

This report presents information about Coeliac UK and its dormant subsidiary undertaking, Coeliac Trading Company Ltd (Company number 02856981). The assets and operations of the trading company were transferred to Coeliac UK in 2023, and the Directors of the subsidiary have decided that the company shall remain dormant for the foreseeable future.

### Our Approach to Fundraising

As a charity registered with the Fundraising Regulator, we strive to achieve the highest standards in all our fundraising activities, referring to all relevant professional and statutory bodies as guidance and regulation develops. Our aim to develop positive long-term relationships with our members, donors and supporters underpins all our actions in this area.

Coeliac UK operates with a small team of in-house staff to lead and develop its fundraising. Fundraising staff are expected to act professionally at all times, follow the Fundraising Regulator's Code of Conduct (as updated from time to time) and are encouraged to undertake relevant training to develop their knowledge. Fundraising staff receive a salary but are not eligible for a performance bonus.

---

# **Coeliac UK**

## **Annual Report and Financial Statements for the year ended 31 December 2025**

---

We also use the services of several carefully selected external companies who provide specialist skills to help us deliver specific activities. These include a telephone agency, as well as a raffle and lottery manager. With each of these companies, we have signed agreements, committing them to adhere to both the letter and spirit of the regulations.

Any complaints that fundraising activity may generate are recorded and investigated by the appropriate line manager to ensure future learning opportunities in fundraising. Coeliac UK is pleased that its fundraising activity generates few complaints annually. In 2025, we received 11 complaints. All complaints were quickly resolved without escalation.

### **Managing Risk**

The Trustees are responsible for ensuring appropriate financial and other controls are in place. At Coeliac UK, the role of risk management is delegated to the Audit, Investment and Risk Committee (AIRCom) who review the risks and report to the Board.

A risk register is used by the Board and staff to review the main risks and uncertainties, and controls are put in place for management and mitigation as necessary. The register is regularly updated and monitored by the executive team, Committees and Board as work progresses and new risks emerge.

The principal risks which could seriously affect the Charity are made up of financial, operational, regulatory, external and strategic risks; and the main residual high risk identified (after controls and mitigating actions) in 2025 was that income generated from all channels does not meet the budget target, impacting the Charity's ability to fulfil its charitable objects. The Charity continues to develop additional and alternative income streams to grow overall income and offset fluctuations in individual areas. Expenditure is carefully monitored and managed to protect the delivery of the Charity's services and financial sustainability.

# Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2025

## Report of the Board of Trustees

The Board of Trustees who are the Charity Trustees, and Directors of Coeliac UK ('the charitable company'/'the Charity'), have pleasure in presenting their report, which incorporates the report of the Directors for the purposes of company law, and the accounts for the year ended 31 December 2025.

### Introduction

2025 was a year of resilience, progress, and renewed ambition for Coeliac UK. In a period marked by economic pressures and evolving healthcare challenges, we remained steadfast in our mission: to ensure that no life is limited by coeliac disease.

We responded to a demanding external environment with focus and determination. The cost-of-living crisis continued to affect access to gluten free food, placing additional strain on individuals and families already managing a lifelong medical condition. Throughout the year, Coeliac UK worked to highlight these challenges, influence policy, and deliver practical support that makes a measurable difference to people's lives.

Our 2024 strategic review reaffirmed the strength of our direction and the continued relevance of our mission. By refining our vision, mission, and values, we renewed our long-term commitment to improving diagnosis, access, and quality of life for everyone affected by coeliac disease.

During 2025, we prepared the organisation for the launch of our new five-year strategic plan in 2026. This forward-looking plan builds on solid foundations and focuses on three strategic areas: Diagnosis and Equality, Support and Access, and Research and Advocacy. Through these pillars, we are working to ensure faster diagnosis, stronger support, and better care for all - while driving research that advances new treatments and brings us closer to a cure.



# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025



Our ambitions are bold. We aim for every person with coeliac disease to receive a diagnosis soon after they experience their first symptoms. We will continue to expand access to gluten free food, advocate for policy change across the food and health sectors and invest in research to improve the lives of those affected today - while laying the groundwork for new treatments and a cure.

None of this progress would be possible without the unwavering dedication of our staff, volunteers, members, partners, and donors. Their contributions - of time, funding, and expertise - are central to our success. Together, we are creating tangible change and building a stronger future for people living with coeliac disease.

To support this, and alongside the introduction of our new strategy, we refreshed our values to better reflect how we work together and engage with our stakeholders.



As we look ahead, we remain confident and focused on delivering real, sustainable impact. Through collaboration, innovation, and evidence-based advocacy, Coeliac UK will continue to lead the way in improving understanding, shaping policy, and transforming lives.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Major Achievements and Impact

Against a challenging operating environment, especially for the charitable sector, we are incredibly proud of our achievements in 2025. For more details, please see our [2025 Impact Report](#) which is available on our website. Some highlights include:

- In March 2025, flanked by a powerful crowd of volunteers, health care professionals, MPs, Peers, and BBC journalists we handed a petition signed by more than 22,000 people, asking the Government to review gluten free prescribing in England into 10 Downing Street.
- Conducted an international research call attracting over 40 different projects with c. £10 million of potential research activity.
- Achieved charity-based sector leading member renewal rates of c. 85%.
- Over 70k people engaged with our content on social media, increasing understanding of many symptoms, from fatigue to numbness.
- We were grateful to receive significant financial support from our community, including more than £1.44 million through Gifts in Wills.
- £900k income from our trusted commercial partners, as well as a donation of £20,000 from BFree through an on-pack donation activity during the coeliac disease awareness month of May.
- Nearly 70k people visited our 'Is It Coeliac Disease?' website and were encouraged to pursue a diagnosis, up over 50% on 2024.

### Diagnosis & Equality

We continued our work to increase the number of people diagnosed with coeliac disease and strive for greater equity to the diagnosis pathway.

Our Coeliac Awareness Month (run throughout May) garnered huge media coverage, including diverse case studies covering a range of symptoms. Aiming to increase knowledge about coeliac disease, our awareness raising work also empowered nearly 70,000 people to begin their diagnosis journey by completing the 'Is It Coeliac Disease?' assessment.

Our network of healthcare professional members is crucial in enabling people to access a diagnosis as well as providing ongoing care in both primary and secondary healthcare settings. This network grew again in 2025, as we reached out to even more GPs, and consequently a wider group of patients.

In 2025, we helped thousands of people feel safer after downloading our resources. We also helped parents and caregivers feel more confident about their child's gluten free diet, with nearly 9,000 resources downloaded for children and young people. More young people learnt to stay well after leaving home with many downloading our 'Moving On' packs.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Support

We are here for everyone who needs to live gluten free. In 2025, we continued to work relentlessly for all our community including over 60,000 members.

With support from across the Coeliac UK community, we ran a wide range of inspiring gluten free food events across the UK, including local meet-ups and specialised food festivals to help people live gluten free. We were delighted to engage with thousands face to face at community led events, Coeliac UK activities, regional shows, festivals, and events across the UK, helping everyone to feel included, supported and less isolated.

Our volunteers led over 500 events across the UK.

More than 3,000 people attended 2 major Gluten Free Food Markets, in Edinburgh and Torquay, with a total of 26 specialist exhibitors.

Staff and volunteers supported 3 'Free From' Festivals in Bristol, London, and Birmingham.

Our website proved again that it is a vital resource for everyone, with over 1 million active visits. We developed a new, modernised website during 2025 that launched in January 2026. The new website will enhance user experience and ensure easier access to the right information to support their needs.

We also welcomed even more people to join our trained volunteers growing this group by 20%, all of whom helped to deliver over 500 community events, nationwide. We are especially delighted to see that our Teen Virtual Club has supported over 100 teenagers with coeliac disease, enabling them to share their experiences with one another as well as an enjoying a 'cookalong' with Becky Excell. Young people of all ages were supported through our printed and online materials, with 348 packs distributed.

Our Helpline services continue to support every aspect of living gluten free, managing over 18,000 enquiries this year, providing a vital lifeline to many people who have nowhere else to turn. Over 250 families were supported through our dietitian-led diet and health workshops, receiving glowing feedback.

Despite technical challenges that, unfortunately, led to temporary access issues for our members, the Food Information Service remains a valuable source of support for our community, with an average of over 9,000 web and app visits every month. Featuring information on over 190,000 food products, with the app version adding an extra dimension of a barcode scanner, making shopping gluten free much easier.

Our knowledge of the community and their needs was further demonstrated by the use of the Home of Gluten Free Recipes. The service had an average of over 30,000 visits a month, peaking in December.

### Access

As the gluten free diet is the only treatment for coeliac disease, the availability of gluten free alternatives, and people's ability to access them, are focus areas that continue to drive our efforts.

Working together with food industry partners, through our food safety schemes and pulling on our expertise, we work to ensure that their products are safe, suitable, and attractive to our community.

---

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

With the Crossed Grain trademark (CGT) scheme (available to be used throughout the world), manufacturers can easily show to consumers which products are suitable for a gluten free diet. We were delighted to welcome more new manufacturing partners to this food safety scheme in the UK during 2025, meaning that nearly 2,000 food products now carry the CGT in the UK.

Eating out of the home continues to be one of the biggest challenges for people with coeliac disease, as the danger of cross-contamination, where even a small crumb of gluten can re-ignite the devastating immune reaction that causes damage, is harder to control.

The Gluten Free Accreditation (GFA) scheme for caterers provides a great support to those who work in the catering industry, assisting and supporting them to develop the best processes, checks, menus, and service for people who need a gluten free diet. At a time when venues are facing a combination of operating challenges, we were delighted to recruit a small number of new GFA partners slightly increasing the number of venues and locations throughout the UK that have confidence in providing gluten free meals to over 2,500, supporting our community wherever they are.

We work closely with schools, caterers, and food businesses to improve everyday life for people with coeliac disease. It is now easier to eat out, thanks to more than 2,500 food venues in the UK securing our GFA. This means they follow our strict standards, processes, and training for serving gluten free food.

We want diners to eat out with total confidence, so in 2025, we also undertook a full review of the standards which underpin our GFA, adding stronger requirements and improved guidance. As a result, our partners are better equipped than ever to minimise the risk of gluten. The training programmes linked to these food safety schemes are also vital additions to ensure gluten free food is available.

Elsewhere, our regular communications to members and the wider Coeliac community means we can offer manufacturers the opportunity to promote their products, particularly new additions, to this audience. We would like to acknowledge the support of Warburtons, Panasonic, Genius, Coop, Nestle GoFree, and Dr Schar for their sponsorship of some of our key activities.

Coeliac UK is uniquely placed to recognise and understand both the needs of people who require a gluten free diet, and the requirements of companies who can provide those products. Additionally, our expertise in the gluten free diet, amassed over nearly 60 years, means we have the knowledge and competency to represent our community on the global stage.

Thanks to the support of our community, we work with partners globally to improve diagnoses, treatment, policy, and standards everywhere. In 2026, the World Health Organisation and Food and Agriculture Organisation are taking a better approach to gluten, thanks to our influence.

After reviewing Coeliac UK's policy briefings, evidence and data, the precautionary allergen framework ("may contain") now does more to protect those with coeliac disease, or a wheat allergy.

In 2026, we will ensure these new guidelines are applied correctly and do not impact the threshold of 20 parts per million for gluten free labelling.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Advocacy

Representing the views and needs of our community has always been a key mission for the charity, and this becomes more important each year. The cost-of-living difficulties being encountered by so many people, can affect those on a gluten free diet disproportionately as many of their food costs are markedly higher. In 2025, we continued to fight for everyone with coeliac disease, championing change with powerful policy makers.

With gluten free food still hard to access, and costly, many people with coeliac disease still rely on prescriptions to eat safely. And we worked hard in 2025 to protect them. Thanks to our campaigning, coeliac disease has moved up the agenda in top government conversations.

Following sustained engagement with the Welsh Government and commissioners, a new gluten free food subsidy card scheme has been agreed and is due to launch in 2026. The scheme will provide people in Wales with a more flexible option to purchase discounted gluten free food in retail settings.

In March 2025, we presented a petition signed by more than 22,000 people to 10 Downing Street, calling on the Government to review the provision of gluten free prescribing in England. We were supported by volunteers, healthcare professionals, MPs, Peers, and national media, including the BBC. The campaign achieved extensive national coverage, with an estimated advertising value exceeding £2 million. Media impact was further strengthened by public support from Rebecca Adlington OBE and a live interview on BBC Breakfast.

Following our petition, the issue was raised in Parliament 17 times – a four-fold increase compared to 2024. And broader mentions of coeliac disease in Parliament shot up by 50%.

### Research

During the year, Coeliac UK launched its first uncapped, open research funding call, enabling researchers worldwide to apply for funding for coeliac disease research. The approach was designed to ensure research investment is guided by identified evidence gaps and potential public benefit, while broadening engagement across the research community.

The charity received 41 initial applications, representing potential funding of approximately £10 million. After peer and lay review, the Research Awards Panel recommended three projects for funding, totalling £661,597, subject to conditions. These recommendations were approved by the Board as part of the 2026 budget process.

In addition, funding available from donations, grants, and legacy income, together with reserves carried forward, enabled the charity to approve a further £139,000 award to the University of Oxford to continue research into the role of rogue immune cells in coeliac disease.

Coeliac UK believes that investing in early career research is essential to build the future research skills needed to achieve our strategic ambitions. In 2025, the Charity approved funding for four sponsored undergraduate dissertations of up to £5,000 each.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Plans for 2026

In 2026 and beyond, the Charity will continue to focus on delivering objectives that are aligned with the strategic pillars which support our mission for no life to be limited by coeliac disease.

### Diagnosis & Equality

A key focus in 2026 will be increasing diagnosis of coeliac disease through awareness activities, underpinned once again, by our flagship Awareness campaign in May. This campaign will target individuals with undiagnosed symptoms, those requiring ongoing support, healthcare professionals, and commercial partners. Community engagement will expand through social media, online events, and in-person initiatives, targeting a wider demographic.

We will continue our core work around improving diagnosis, contributing to the development of updated guidelines for coeliac disease and associated conditions such as Type 1 diabetes, faltering growth, and autoimmune thyroid disease. We will participate in healthcare professional (HCP) education days and initiate a new Clinical Champions programme to promote best practices in diagnosis, treatment, and long-term support. Additionally, we aim to raise awareness among healthcare professionals beyond GPs, gastroenterology and dietetics, including dentists, hepatologists, and mental health practitioners.

### Support

We will implement a comprehensive review of our membership model and package options to ensure they effectively give access to the value of our expertise, support services, and resources for anyone who needs them. This process will inform a refined membership proposition aligning with our strategic goals. Our efforts will focus on four key themes:

- Community Support – Strengthening networks and connections for those affected by coeliac disease.
- Community Value – Enhancing the benefits and resources available to members.
- Community Growth – Expanding our reach and engagement with new and existing audiences.
- Community Impact – Driving positive change and raising awareness through collective action.

Again in 2026, we will be expanding support for community events. This will include increasing the number of volunteer-led local activities across the UK, being present at several external food festivals and organising national Gluten Free Food Market(s) to bring together consumers, businesses, and experts in one space.

We will also continue to develop dedicated support resources for children and young people, providing opportunities for peer connection and ensuring age-appropriate tools and information are readily available.

### Access

As part of our commitment to delivering value, we will continue our validation work across all services, ensuring:

- Off the shelf product sampling for gluten analysis remains a key feature within our Food Information Service.
  - Gluten free training credentials are verified for all venue guide recommendations.
  - Factsheets and publications are evidence-based and reflect best practices.
-

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

Additionally, we will continue to share our dietetic and health professional expertise by delivering dietitian-led workshops, support videos, and new webinars throughout 2026.

We will focus on enhancing access to safe gluten free food by promoting our food safety schemes, the Crossed Grain Trademark (CGT) and relaunched Gluten Free Accreditation (GFA).

The GFA scheme will continue to target hospitality, healthcare, education, and retail sectors, with a structured rollout plan for new accreditations under our GFA Standard that was updated in 2025.

Our digital transformation efforts will enhance the availability of information for existing and potential commercial customers, through our dedicated microsite for food businesses launched in 2025.

### Advocacy

Advocacy efforts in 2026 will continue to build upon previous work on the cost of gluten free foods, access to safe gluten free options in public sector settings, improving diagnosis and management of coeliac disease. We will continue public affairs work to engage policymakers across all four nations, host parliamentary events, and pursue meetings with Health Ministers.

We will ensure that coeliac disease and the gluten free diet remain a focus at both national and international levels e.g. at the Codex Alimentarius, the most important international body in the field of food standards. We will support ongoing research on gluten thresholds and reference doses to provide further evidence to underpin key food standards that will improve conditions for our community.

### Research

Our research program will always remain a priority, with continued funding in line with our research priorities, such as studies that may identify key targets in coeliac disease that could lead to new treatment opportunities beyond the gluten free diet. Indeed, Coeliac UK is currently the largest single funder of research into coeliac disease in the UK and one of the largest in the world. Since 2005, the charity has committed more than £3.5 million to research.

Following the Board's approval, in 2026, we plan to support the project of Professor Ludvig Sollid on tissue proteomics to combat coeliac disease, Dr Vincent van Unen of The Netherlands work into infections as early triggers of loss of gluten tolerance in genetically at-risk Children, and validation of coeliac disease specificity of four candidate T-cell receptor gamma sequences with high diagnostic potential, led by Prof Soilleux in the UK.

Additionally, we will conduct a study on the epidemiology and health economics of coeliac disease - to understand current diagnosis rates and prevalence of coeliac disease to support the focus of our work, and how the disease is reflected in the UK population

### People and Culture

In 2026 and beyond, we will continue to articulate and embed our new values of Tenacious, Caring, Trustworthy, and Collaboration, and invest in training, development, and recruitment to retain and attract top talent.

A key activity is the development of the Coeliac UK Employee Value Proposition, which will include a comprehensive review of employee benefits. We will continue to promote staff wellbeing, through regular satisfaction and mental health surveys and improving employee experience through agreed workplace improvements.

---

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Technology

Having launched our new website in 2026, we will focus on enhancing the online experience for all stakeholders. Elsewhere, we will continue to invest and develop our technology solutions, and explore AI deployment, and systems integrations to enhance quality, productivity and efficiency in how we work to achieve our strategic objectives.

### Engagement

We will continue to develop long-term relationships with supporters and broaden our portfolio of voluntary income streams. Our approach will ensure that supporting Coeliac UK is a positive and fulfilling experience by improving how we engage, steward, and thank donors.

A key strategic focus is to increase sustainable income by growing the number of regular donors. We aim to expand recurring giving across a range of channels, including membership-linked donations, direct debits, payroll giving, and recurring card payments. Following the launch of the new membership offering, we will explore further opportunities to encourage regular and value-added giving.

Income from our lottery and raffle activities, including the Gluten Free Weekly Lottery, remains an important revenue stream for the charity. During the year, the focus will be on extending the reach of the lottery beyond the membership base through targeted digital and face-to-face engagement. Raffles will continue to be developed as a cost-effective fundraising channel, with emphasis on maximising participation and income generation.

Challenge events offer both financial support and an opportunity to engage new audiences. In 2026, we will continue to increase the number of places available in key events while encouraging individuals to enter events on their own initiative. Enhanced supporter stewardship will maximise funds raised and provide compelling case studies for broader charity use.

To sustain core activities and increase our research funding, we will continue our efforts to grow individual giving. This will include at least one dedicated appeal for research funding utilising a peer-reviewed project aligned with the Charity's vision. Donation requests will feature prominently on the new website and in supporter newsletters and other communications.

The introduction and recruitment of a new role, Head of Philanthropy, will help to develop our fundraising from Major Donors as well as continue the excellent work to date in developing income from gifts in wills. We will reach out to trusts and foundations to seek their support in finding a cure for coeliac disease, as well as selected corporate partners.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Financial Review

#### Overview

The Charity's income is generated primarily from three sources: membership fees; commercial services, including the restaurant accreditation scheme and licensing of the Crossed Grain Trademark; and fundraising from donations, including gifts in wills. Additional income is generated through raffles and the weekly lottery, as well as grant income.

These funds enable the Charity to deliver services and information to support people diagnosed with coeliac disease, or those caring for someone with the condition, to live a gluten free life, and to provide guidance to those seeking diagnosis. The Charity also campaigns with the health and food sectors to raise awareness, improve understanding of the condition and promote appropriate treatment. Over the longer term, these income streams support investment in research to improve disease management, develop potential treatments and ultimately work towards a cure.

The Charity reported a net deficit of £139k for 2025, an improvement of nearly £300k compared to 2024 (£436k). Total income in 2025 was £4,845k, an increase of £367k from £4,478k in 2024. The increase was driven primarily by income from gifts in wills, which totalled £1,441k in 2025, compared to £760k in 2024. This growth reflects long-term investment in legacy fundraising. Overall income from donations and legacies was £2,372k, representing an increase of £594k (33%) on 2024 (£1,778k). Income from challenge events also performed well and is expected to be an area of future growth. By contrast, income from raffles and the lottery (trading activities) declined during the year and activity will be reviewed in 2026.

Income from trading and charitable activities totalled £2,408k in 2025, a decrease of £223k (8%) compared with £2,631k in 2024. This reduction was largely attributable to lower membership income, reflecting continued migration from full to digital memberships, lower than expected reactivation of lapsed members, and a change in accounting treatment for annual memberships purchased in advance. This accounting change resulted in a one-off reduction in reported income of approximately £180k on a like-for-like basis.

Investment income totalled £65k in 2025, a decrease of 6% compared to £69k in 2024, comprising £23k in bank interest (down £4k) and £42k in dividend income (unchanged from 2024).

Total expenditure increased to £5,051k in 2025, compared with £4,951k in 2024. This increase was largely driven by higher expenditure on raising funds, particularly donations and legacies, which increased by £140k, reflecting continued investment to grow regular donations and establish new sources of sustainable income.

Expenditure on trading activities (raffles and lottery) also increased by £43k, although income in this area fell; activity in this area will be reviewed in 2026 to improve return on investment.

Spending on charitable activities decreased slightly from £4,015k to £3,931k, of which total research expenditure reduced from £449k in 2024 to £344k in 2025, including £158k in grant awards.

Our focus in 2026 will be on continuing to develop the broader portfolio of sustainable income streams, and careful management of expenditure, to ensure that we achieve a good return on investment for our members, donors and supporters and deliver improving outcomes for our beneficiaries in line with our strategic and charitable objectives.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Investing in research

In 2024, we made grant awards £360k (though this was offset by the withdrawal of an unspent award of £91k in research awards in 2024), We made further awards of £158k in 2025 to both better understand the role of rogue cells in coeliac disease (£139k), and four dissertations to encourage early career researchers and explore potential new areas of research (£19k).

### Investment policy and Performance

The objective of the Charity's Investment Policy is to achieve a return on the charity's investment assets, including cash and other liquid or short-term investment assets, to further the charity's aims and meet the charity's future funding requirements whilst having regard to the risk parameters agreed by the Board of Trustees. The portfolio should provide a return (after any fees) that at a minimum matches or betters inflation while preserving the capital value. The Charity should also retain sufficient liquid resources to enable it to effectively meet its short-term obligations and provide adequate cover to meet any unplanned or unbudgeted expenditure. Furthermore, to ensure that environmental, social and governance (ESG) impact of the investment funds are considered, the charity's assets are not invested in shares or any other financial instrument of a company whose objectives are contradictory to those of Coeliac UK.

Funds that are unlikely to be required over the long-term (5 years or more) are invested in long-term capital funds, whilst funds required in the short-term are invested in low risk but high liquidity interest-bearing funds.

In 2025, short-term cash deposits were invested in the overnight money market (HSBC). Bank interest received from our cash deposits in 2025 was £23.6k.

In addition, at 31 December 2025 the Charity had £1,037k invested with fund manager Cazenove Capital, in their "Charity Sustainable Multi Asset Fund", which the Trustees are satisfied meets its objectives as described in the Investment Policy. In 2025, this fund paid dividends of £41.6k and achieved a gain of £67.6k.

The Charity regularly reviews its cash and investment position and released gains of £50k to rebalance assets between long and short term investments. We will continue to monitor balances and consider further investment in 2026.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Reserves policy

The Board recognises the need to hold charitable funds as free reserves to safeguard the continuity of provision of basic services, to fund periods of expenditure in excess of revenue and to fund unexpected expenditure.

As part of the 2025 year-end review process, the Board of Trustees used Charity Commission guidelines to conduct an annual review of the reserves policy.

The Board agreed to maintain the existing policy: that sufficient reserves will be held to ensure the Charity can continue to operate and meet its charitable commitments, should there be a time when income has been adversely impacted. This is to allow time to assess and implement the future options for the Charity. Excess reserves will be designated for a specific activity when an appropriate and timely use of the funds has been identified and agreed by the Board. In the event there are no extra reserves, the Board may utilise the operational reserves to meet any of the above needs should they arise, subject to a cost benefit analysis.

The target level of reserves as of 31 December 2025 has been calculated at £991k, being the midpoint within the reserves policy range of £776k to £1,205k. The Reserves target is calculated by assuming an average reduction in forecast income of 25% offset by a forecast reduction in discretionary costs, equal to a reduction in total costs of approximately 7.5%. We ended the year with unrestricted reserves of £1,201k, some £211k above the target. We will continue to invest our surplus reserves in our charitable activities over the next strategic period.

The Board also agreed to maintain a level of liquid reserves that ensures the Charity can meet its obligations as they fall due. The level of liquid reserves required and liquid reserves available is reviewed regularly throughout the year. On 31 December 2025 the Charity had £1,732k in liquid assets, comprising £695k cash and £1,037k in other liquid investments.

Of our restricted reserves of £268k, we had £224k held for our Research Fund. From time to time, we raise funds solely for research to build a sufficient sum to launch a research call for grant applications.

### Going Concern

Management and the Trustees regularly review detailed forecasts of income, expenditure and cash flow. The assumptions underlying the budget and forecasts are challenged, varied and tested to establish the likelihood of a range of possible outcomes including reasonable cash flow sensitivities. The forecast performance is monitored against actual outcomes each month and variances analysed and discussed at Management and Board level.

The Trustees have reviewed cash flow forecasts for the period to 31 December 2027. The cash flow forecasts indicate that the Charity will be able to meet its liabilities as they fall due for the period until at least 31 December 2027. If income does not achieve projected levels, management is able to adjust discretionary expenditure to relieve any short-term cash pressures which might arise.

The Trustees are therefore satisfied that the financial statements should be prepared on the going concern basis.

## Coeliac UK

### Annual Report and Financial Statements for the year ended 31 December 2025

---

#### Responsibilities of the Board of Trustees

The Board of Trustees (who are also directors of Coeliac UK for the purposes of company law) is responsible for preparing the Report of Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Board of Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the charities (SORP) FRS102;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Board of Trustees is responsible for keeping adequate accounting records which are sufficient to show and explain the charitable company's transactions and which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and the Charitable Company's constitution. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the Board of Trustees are aware:

- there is no relevant audit information of which the charitable company auditor is unaware; and
- the Board of Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Board of Trustees is responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the Special Provisions of Part 15 of the Companies Act 2006 relating to Small Companies.

This report was approved and authorised for issue by the Board of Trustees on 8 June 2026 and signed on their behalf by:



---

**Chris Dilloway** Chair  
Registered Company Number: 03068044

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Independent auditors' report to the members and trustees of Coeliac UK

#### Opinion

We have audited the financial statements of Coeliac UK ('the parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2025 which comprise the group statement of financial activities, group and parent charity balance sheet and group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

#### In our opinion the financial statements:

- give a true and fair view of the charitable company's state of the affairs of the group and the parent charitable company as at 31 December 2025 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRCS Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

#### Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

---

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

*Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact.*

We have nothing to report in this regard.

### **Other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Board of Trustees which includes the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Board of Trustees which includes the Directors' Report has been prepared in accordance with applicable legal requirements.

### **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Board of Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemption in preparing the Report of the Board of Trustees and the Strategic Report.

### **Responsibilities of Trustees**

As explained more fully in the Statement of Responsibilities of the Board of Trustees set out on page 20, the Trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under the Companies Act 2006 and under the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud.

---

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered
- that the most significant are the Companies Act 2006, the Charities Act 2011, the Charity SORP, the Charities and Trustee Investment (Scotland) and UK financial reporting standards as Issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected noncompliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify Instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of noncompliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

### Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members and trustees as a body, for our audit work, for this report, or for the opinions we have formed.

# Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2025

---

Signed by:  
*Moore Kingston Smith LLP*  
FE06C486F34044F...

**James Saunders (Senior Statutory Auditor)**  
**Moore Kingston Smith LLP**  
**Statutory Auditors**

Date: 15/6/2026  
**9 Appold Street**  
**London**  
**EC2A 2AP**

**Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.**

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Consolidated statement of financial activities (including consolidated income and expenditure account)

	Notes	Unrestricted funds (£)	Restricted funds (£)	2025 Total (£)	2024 Total (£)
<b>Income</b>					
Donations and legacies	2	2,075,590	296,360	2,371,950	1,778,379
Income from charitable activities	2	1,897,039	30,000	1,927,039	2,115,875
Income from trading activities	2	480,961	-	480,961	515,224
Investment income	2	65,167	-	65,167	68,522
Other Income		-	-	-	-
<b>Total income</b>		<b>4,518,757</b>	<b>326,360</b>	<b>4,845,117</b>	<b>4,478,000</b>
<b>Expenditure</b>					
Expenditure on raising funds					
Donations and legacies		621,397	55,230	676,627	544,066
Trading activities		443,378	-	443,378	407,802
Expenditure on charitable activities	3	3,683,215	248,064	3,931,279	3,999,516
<b>Total expenditure</b>		<b>4,747,990</b>	<b>303,294</b>	<b>5,051,284</b>	<b>4,951,384</b>
<b>Net gains on investments</b>	11	<b>67,585</b>	<b>-</b>	<b>67,585</b>	<b>37,389</b>
<b>Net Income/(expenditure) for the year</b>	7	<b>(161,648)</b>	<b>23,066</b>	<b>(138,582)</b>	<b>(435,995)</b>
<b>Balances brought forward</b>		<b>1,670,623</b>	<b>245,090</b>	<b>1,915,713</b>	<b>2,351,708</b>
<b>Total funds carried forward</b>		<b>1,508,975</b>	<b>268,156</b>	<b>1,777,131</b>	<b>1,915,713</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The notes on pages 29 to 45 form part of these financial statements.

**Coeliac UK****Annual Report and Financial Statements for the year ended 31 December 2025****Consolidated balance sheet**

	<b>GROUP</b>		<b>CHARITY</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>FIXED ASSETS</b>				
Tangible assets	119,880	157,966	119,880	157,966
Intangible Assets	126,814	121,173	126,814	121,173
Investment & deposits	1,037,554	1,019,969	1,037,554	1,019,969
	<u>1,284,248</u>	<u>1,299,108</u>	<u>1,284,248</u>	<u>1,299,108</u>
<b>CURRENT ASSETS</b>				
Sundry Debtors	1,546,612	1,699,957	1,546,612	1,699,957
Cash at Bank	694,549	799,545	694,530	799,485
	<u>2,241,161</u>	<u>2,499,502</u>	<u>2,241,142</u>	<u>2,499,442</u>
<b>CURRENT LIABILITIES</b>				
Creditors - falling due within one year	(1,730,278)	(1,873,897)	(1,730,278)	(1,873,896)
	<u>510,883</u>	<u>625,605</u>	<u>510,864</u>	<u>625,546</u>
<b>NET CURRENT ASSETS</b>				
<b>Total assets plus current liabilities</b>	1,795,131	1,924,713	1,795,112	1,924,654
<b>Provisions for liabilities and charges</b>	(18,000)	(9,000)	(18,000)	(9,000)
<b>NET ASSETS</b>	<u>1,777,131</u>	<u>1,915,713</u>	<u>1,777,112</u>	<u>1,915,654</u>
<b>The funds of the charity</b>				
Unrestricted funds				
Designated	31,047	45,640	31,047	45,640
General	1,477,928	1,624,983	1,477,910	1,624,924
	<u>1,508,975</u>	<u>1,670,623</u>	<u>1,508,957</u>	<u>1,670,564</u>
Restricted funds	268,156	245,090	268,156	245,090
<b>Total charity funds</b>	<u>1,777,131</u>	<u>1,915,713</u>	<u>1,777,112</u>	<u>1,915,654</u>

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011. These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

As permitted by s408 Companies Act 2006, the company has not presented its own Statement of Financial Activity and related notes. The Company's profit/(loss) for the year was (£138,582), (2024: (£435,995)).

Approved by the Board of Trustees and authorised for issue on 8th June 2026 these financial statements are signed on their behalf by:

**Chris Dilloway - Chair**

Company number: 03068044

The notes on pages 29 to 45 form part of these financial statements.

**Coeliac UK****Annual Report and Financial Statements for the year ended 31 December 2025****Consolidated statement of cash flows**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
<b>Cash flows from operating activities:</b>		
Net cash used in operating activities	(115,826)	(423,960)
<b>Cash flows from investing activities:</b>		
Dividends, interest and rents from investments	41,607	41,836
Bank interest	23,560	26,686
Purchase of fixed assets	(104,858)	(114,559)
Disposal of fixed assets	521	-
Purchase of investments	-	-
Sale of investments	50,000	-
Net cash created by/(used in) investing activities	<u>10,830</u>	<u>(46,037)</u>
<b>Decrease in cash and cash equivalents in the year</b>	<b>(104,996)</b>	<b>(469,997)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>799,545</b>	<b>1,269,542</b>
<b>Total Cash and cash equivalents at the end of the year</b>	<b><u>694,549</u></b>	<b><u>799,545</u></b>

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### 1 ACCOUNTING POLICIES

#### 1.1 Basis of preparation

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK (FRS102) and (Charities SORP (FRS 102) and the Companies Act 2006.

Coeliac UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

There are no material uncertainties about the charity's ability to continue as a going concern. The charity's planned activities, together with its financial position; management of risk and approaches to investments, cashflow and reserves are described in the Report of the Board of Trustees. As a consequence, the Trustees believe that the charity is well placed to manage its risks successfully despite the current uncertain economic outlook. The Trustees have a reasonable expectation that the charity and the group have adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and accounts.

#### 1.2 Local groups and accounting policy

The local groups record their income and expenditure on a receipt basis. At the end of the financial year, each group submits a return of its income and expenditure which is included in the Statement of Financial Activities and the Balance Sheet.

#### 1.3 Income

Income from web advertising, sponsorship and licensing, and accreditation is deferred on a proportionate basis over the life of the contract. All other income is recognised when the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Donations and legacies includes donations and gifts, legacies, and all other income that is in substance a gift made on a voluntary basis. It also includes grants of a general nature provided by government and charitable foundations which are not conditional on delivery of certain levels or volumes of a service. The donation may be made towards the general aims of Coeliac UK (unrestricted), or towards a specific service or aim (restricted). Donations are recognised on receipt of the donation, or if earlier, at the point where there is a written obligation for a donor to pay a specified donation. Legacies are recognised at the point entitlement is established, receipt is considered probable and the estate value can be estimated reliably.

#### 1.4 Cost allocation

Shared costs have been allocated on the following basis:

Description	Method of apportionment
Depreciation	Head count
Information technology	Head count
Support staff costs	Head count
Office costs	Head count

#### 1.5 Grants

Grants payable are payments made to third parties in furtherance of the charitable objectives.

Grants which are free from specific conditions are recognised in full as soon as there is a legal or constructive obligation committing the charity.

Where Multiyear grants are conditional on an annual review of progress which will determine if future funding is provided, no more than two year's funding commitment is recognised.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### 1 ACCOUNTING POLICIES (Continued)

#### 1.6 Restricted funds

Restricted funds are to be used for specific purposes as specified by the donor. Expenditure which meets these criteria is charged to the fund.

#### 1.7 Depreciation of fixed assets

Provision is made for depreciation on all tangible assets at rates calculated to write off the cost, less estimated residual value of each asset over its expected useful life, as follows:

Furniture and fittings	20% p.a. straight line
Computer equipment	33.33% p.a. straight line

#### 1.8 Investments & Deposits

Investments held as fixed assets are revalued at market value at the balance sheet date.

#### 1.9 Leasing

Rental payable under operating leases are charged against income on a straight-line basis over the lease term.

#### 1.10 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of obligation can be measured reliably. Costs are analysed between expenditure on charitable activities and costs of raising funds of the charity. Any direct costs are allocated between restricted and unrestricted funds as incurred.

#### 1.11 Designated funds

Designated funds are unrestricted funds earmarked by the board of Trustees for particular purpose.

#### 1.12 Pension

The charitable company operates a group personal money purchase pension scheme. The pension cost charged in the financial statements represents contributions payable by the charity during the financial year.

#### 1.13 Basis of consolidation

The group accounts consolidate the accounts of Coeliac UK and its subsidiary undertaking on a line by line basis. The accounts are made up to 31 December 2025. No separate statement of financial activities or income and expenditure has been presented for the charity alone as permitted by section 408 of the Companies Act 2006.

#### 1.14 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

#### 1.15 Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

#### 1.16 Intangible Asset Policy

Intangible assets are assets that lack physical substance but have value. Intangible assets are recognised at cost, which includes the purchase price and any directly attributable costs of preparing the asset for its intended use. Intangible assets are amortised over their useful life, capped at three years.

#### 1.17 Cash Policy

Cash comprises cash on hand and demand deposits.

Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

# Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2025

## Notes to the financial statements

### 2 INCOME

	Unrestricted	Restricted £	2025 Total £
<b>Income from donations and legacies</b>			
Donations and gifts	780,959	149,751	930,710
Legacies	1,294,631	146,609	1,441,240
	<b><u>2,075,590</u></b>	<b><u>296,360</u></b>	<b><u>2,371,950</u></b>
<b>Income from charitable activities</b>			
Support	912,741	0	912,741
Diagnosis	24,942	30,000	54,942
Access	953,927	0	953,927
Advocacy	0	0	0
Research	5,429	0	5,429
	<b><u>1,897,039</u></b>	<b><u>30,000</u></b>	<b><u>1,927,039</u></b>
<b>Income from trading activities</b>			
Raffle and lottery	479,020	0	479,020
Other commercial activities	1,941	0	1,941
	<b><u>480,961</u></b>	<b><u>-</u></b>	<b><u>480,961</u></b>
<b>Investment Income</b>			
Investments - dividends	41,607	0	41,607
Bank interest	23,560	0	23,560
	<b><u>65,167</u></b>	<b><u>-</u></b>	<b><u>65,167</u></b>

# Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2025

## Notes to the financial statements

### 2 INCOME

	Unrestricted	Restricted £	2024 Total £
<b>Income from donations and legacies</b>			
Donations and gifts	778,494	239,990	1,018,484
Legacies	740,595	19,300	759,895
	<b><u>1,519,089</u></b>	<b><u>259,290</u></b>	<b><u>1,778,379</u></b>
<b>Income from charitable activities</b>			
Support	1,107,021	-	1,107,021
Diagnosis	687	40,000	40,687
Access	949,839	-	949,839
Advocacy	-	-	-
Research	18,328	-	18,328
	<b><u>2,075,875</u></b>	<b><u>40,000</u></b>	<b><u>2,115,875</u></b>
<b>Income from trading activities</b>			
Raffle and lottery	515,224	-	515,224
Other commercial activities	-	-	-
	<b><u>515,224</u></b>	<b><u>-</u></b>	<b><u>515,224</u></b>
<b>Investment Income</b>			
Investments - dividends	41,836	-	41,836
Bank interest	26,686	-	26,686
	<b><u>68,522</u></b>	<b><u>-</u></b>	<b><u>68,522</u></b>
	<b><u>4,178,710</u></b>	<b><u>299,290</u></b>	<b><u>4,478,000</u></b>

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 3a Expenditure

	Unrestricted £	Restricted £	2025 Total £
<b>Charitable activities</b>			
Support	2,021,012	55,404	2,076,416
Diagnosis	171,658	19,596	191,254
Access	1,007,297	-	1,007,297
Advocacy	311,828	-	311,828
Research	171,420	173,064	344,484
	<b><u>3,683,215</u></b>	<b><u>248,064</u></b>	<b><u>3,931,279</u></b>

#### Breakdown of costs of charitable activities

	Direct costs	Grants made (notes 6)	Support costs (note 4, 5)	2025 Total
Support	1,479,466	-	596,950	2,076,416
Diagnosis	124,532	-	66,722	191,254
Access	666,367	-	340,930	1,007,297
Advocacy	198,148	-	113,680	311,828
Research	124,530	157,628	62,326	344,484
	<b><u>2,593,043</u></b>	<b><u>157,628</u></b>	<b><u>1,180,609</u></b>	<b><u>3,931,279</u></b>

#### Research cost breakdown

	Direct costs	Grants made	2025
Direct Research costs	124,530	157,628	282,158
Support costs	-	62,326	62,326
	<b><u>124,530</u></b>	<b><u>219,954</u></b>	<b><u>344,484</u></b>

All support costs are allocated on a headcount basis.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 3b Expenditure

	Unrestricted £	Restricted	2024 Total £
<b>Charitable activities</b>			
Support	1,975,402	173	1,975,575
Diagnosis	191,186	55,241	246,427
Access	1,051,700	-	1,051,700
Advocacy	276,715	-	276,715
Research	216,048	233,051	449,099
	<b><u>3,711,050</u></b>	<b><u>288,465</u></b>	<b><u>3,999,516</u></b>

#### Breakdown of costs of charitable activities

	Direct costs	Grants made (notes 6)	Support costs (note 4, 5)	2024 Total
Support	1,369,914	-	605,661	1,975,575
Diagnosis	174,365	-	72,062	246,427
Access	641,961	-	409,739	1,051,700
Advocacy	162,255	-	114,460	276,715
Research	106,923	268,728	73,448	449,099
	<b><u>2,455,418</u></b>	<b><u>268,728</u></b>	<b><u>1,275,370</u></b>	<b><u>3,999,516</u></b>

#### Research cost breakdown

	Direct costs	Grants made	2024
Direct Research costs	106,923	268,728	375,651
Support costs	-	73,448	73,448
	<b><u>106,923</u></b>	<b><u>342,176</u></b>	<b><u>449,099</u></b>

All support costs are allocated on a headcount basis.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 4 Total support cost breakdown by activity

	Staff costs £	Other costs £	2025 Total £
Cost of raising funds (notes 5)			
Donations and legacies	90,226	88,250	178,476
Trading activities	27,036	26,443	53,479
Charitable activities (note 3)	596,843	583,766	1,180,609
	<b>714,105</b>	<b>698,459</b>	<b>1,412,565</b>

	Staff costs £	Other costs £	2024 Total £
Cost of raising funds (notes 5)			
Donations and legacies	77,516	81,526	159,042
Trading activities	32,653	34,342	66,995
Charitable activities (note 3)	622,971	655,201	1,278,172
	<b>733,140</b>	<b>771,069</b>	<b>1,504,209</b>

#### 5 Support cost apportionment

	Support staff	Depreciation	Governance	HR costs	IT costs £	Office costs £	2025 Total £
<b>Expenditure on raising funds</b>							
Donations and legacies	90,226	17,294	3,708	8,910	32,355	25,982	178,476
Trading activities	27,036	5,182	1,111	2,670	9,695	7,786	53,479
<b>Charitable activities</b>							
Support	301,781	57,842	12,402	29,803	108,220	86,902	596,950
Diagnosis	33,731	6,465	1,386	3,331	12,096	9,713	66,721
Access	172,353	33,035	7,083	17,021	61,807	49,632	340,930
Advocacy	57,470	11,015	2,362	5,676	20,609	16,549	113,681
Research	31,508	6,039	1,295	3,112	11,299	9,073	62,326
	<b>714,105</b>	<b>136,872</b>	<b>29,347</b>	<b>70,523</b>	<b>256,080</b>	<b>205,638</b>	<b>1,412,565</b>

	Support staff	Depreciation	Governance	HR costs	IT costs £	Office costs £	2024 Total £
<b>Expenditure on raising funds</b>							
Donations and legacies	77,516	11,324	4,719	7,568	19,671	38,244	159,042
Trading activities	32,653	4,770	1,988	3,188	8,286	16,110	66,995
<b>Charitable activities</b>							
Support	296,290	43,284	18,039	28,927	75,187	127,296	589,023
Diagnosis	35,169	5,138	2,141	3,434	8,925	17,351	72,158
Access	199,966	29,212	12,174	19,523	50,744	98,659	410,278
Advocacy	55,860	8,160	3,401	5,454	14,175	27,560	114,610
Research	35,686	5,213	2,173	3,484	9,056	36,491	92,103
	<b>733,140</b>	<b>107,101</b>	<b>44,635</b>	<b>71,578</b>	<b>186,044</b>	<b>361,711</b>	<b>1,504,209</b>

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 6 Grants payable

	<b>Grants to institutions</b>	
	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Rogue cell research to better understand coeliac disease MF0323	138,728	103,180
Enzyme inhibitors as a potential treatment for coeliac disease MS0223	-	249,201
Innovate Grant Withdrawn	-	(91,533)
Dissertations Awarded	18,900	7,880
	<b><u>157,628</u></b>	<b><u>268,728</u></b>

In accordance with the accounting policy outlined in note 1.5, only the first year of funding commitment is recognised on the accounts for multiyear grants which are conditional on an annual review of progress which determines if future funding is provided.

#### 7 Net incoming (outgoing) resources for the year

This is stated after charging

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Depreciation	136,782	107,588
Operating lease rentals	50,561	50,681
Trustees liability insurance	1,100	1,100
Audit services	17,950	13,920
Non - audit services provided by the auditors		
General advice	-	-
Tax compliance	2,320	2,320
	<b><u>208,713</u></b>	<b><u>175,609</u></b>

Travel costs amounting to £1,457 (2024 - £2,310) were reimbursed to 5 (2024 - 10) members of the Board of Trustees.

#### 8 Staff costs and numbers

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Salaries and wages	2,423,488	2,256,588
Social security costs	291,274	238,788
Pension costs	129,195	120,102
	<b><u>2,843,957</u></b>	<b><u>2,615,478</u></b>
Redundancy costs are included in the Staff cost shown above	<b><u>27,002</u></b>	<b><u>29,527</u></b>

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

8 The number of employees whose salary amounted to over £60,000 during:

	2025 Number	2024 Number
£120,000-£130,000	1	-
£110,000-£120,000	-	1
£100,000-£110,000	-	-
£80,000 - £90,000	1	-
£70,000-£80,000	2	3
£60,000 - £70,000	1	3

The key management personnel of the group (and charity) comprise the Trustees, the chief executive and senior management team. The total employee benefits ( Salary, Employers National insurance and Employers pension) of the key management personnel of the group were £823,442 (2024: £707,127). None of the Trustees have been paid any remuneration or received any benefits for performing their role as Trustee of the charity.

The average monthly number of employees during the year, calculated on the basis of average headcount was as follows:

	2025 Number	2024 Number
Advice and information	50	49
Administration and support	13	10
	<b>63</b>	<b>59</b>

### 9 Taxation

The charitable company's activities are exempt from corporation tax in its charitable activities under Sections 466 to 493 of the Corporation Tax Act 2010.

### 10 Fixed assets - Group and charity

	Intangible Assets £	Furniture & fittings £	Computer equipment £	Total £	Grand Total £
<b>Cost</b>					
At 1 January 2025	246,850	164,393	54,821	219,214	<b>466,064</b>
Additions	94,744	-	10,114	10,114	<b>104,858</b>
Disposals	(134,010)	-	(11,756)	(11,756)	<b>(145,766)</b>
At 31 December 2025	<b>207,584</b>	<b>164,393</b>	<b>53,179</b>	<b>217,572</b>	<b>425,156</b>
<b>Depreciation</b>					
At 1 January 2025	125,677	32,099	29,149	61,248	<b>186,925</b>
Charge for the year	89,103	32,879	14,800	47,679	<b>136,782</b>
Disposals	(134,010)	-	(11,235)	(11,235)	<b>(145,245)</b>
At 31 December 2025	<b>80,770</b>	<b>64,978</b>	<b>32,714</b>	<b>97,692</b>	<b>178,462</b>
<b>Net book values</b>					
At 31 December 2025	<b>126,814</b>	<b>99,416</b>	<b>20,464</b>	<b>119,880</b>	<b>246,694</b>
At 31 December 2024	121,173	132,294	25,672	157,966	279,139

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 11 Fixed asset investments - Group And Charity

	<b>(Charity only)</b>		<b>Total</b>	<b>Total</b>
	<b>Investments</b>	<b>Unit trusts</b>	<b>2025</b>	<b>2024</b>
	<b>subsidiaries</b>			
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Market Value at 1 January 2025	2	1,019,967	1,019,969	982,580
Additions	-	-	-	-
Disposals	-	(50,000)	(50,000)	-
Realised investment gains/(losses)	-	67,585	67,585	37,389
<b>Market Value at 31 December 2025</b>	<b>2</b>	<b>1,037,552</b>	<b>1,037,554</b>	<b>1,019,969</b>

#### Holdings of more than 20%

The charitable company holds more than 20% of the share capital in the following company:

<b>Company</b>	<b>Country of incorporation</b>	<b>Class</b>	<b>Shares held</b>	<b>%</b>
The Coeliac Trading Company Ltd	England & Wales	Ordinary		100

The Coeliac Trading Company Limited (Company number 02856981) is dormant.  
The address of the registered office is Artisan, Hillbottom Road, High Wycombe, Buckinghamshire, HP12 4HJ.

The aggregate amount of capital and reserves and the results of this undertaking for the year ended 31 December 2025 were:

	<b>Capital</b>	<b>Profits to</b>
	<b>£</b>	<b>reserves for</b>
		<b>the year</b>
		<b>£</b>
The Coeliac Trading Company Ltd	2	-

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 12 Debtors

	Group		Charity	
	2025 £	2024 £	2025 £	2024 £
Trade debtors	179,078	174,913	179,078	174,913
Income tax and VAT recoverable	-	28,030	-	28,030
Amounts owed by group undertakings	-	-	-	-
Prepayments and accrued income	1,367,534	1,497,014	1,367,534	1,497,014
	<b>1,546,612</b>	<b>1,699,957</b>	<b>1,546,612</b>	<b>1,699,957</b>

#### 13 Creditors: amounts falling due within one year

	Group		Charity	
	2025 £	2024 £	2025 £	2024 £
Grants payable	601,455	713,147	601,455	713,147
Trade creditors	207,452	256,193	207,452	256,193
Other tax and social security	68,134	53,792	68,134	53,792
Accruals	170,341	240,071	170,341	240,070
Deferred income	666,899	610,694	666,899	610,694
Income tax and VAT Payable	15,999	-	15,999	-
	<b>1,730,278</b>	<b>1,873,897</b>	<b>1,730,278</b>	<b>1,873,896</b>

#### Deferred income - Charity

	2025 £	2024 £
At 1 January	610,694	503,201
Released in year	(605,242)	(444,002)
Membership, licencing, Lottery and sponsorship income received in advance	661,447	551,495
At 31 December	<b>666,899</b>	<b>610,694</b>

#### 14 Provision for liabilities and charges - Group and Charity

	£
At 1 January 2025	(9,000)
Charged for the year	(9,000)
At 31 December 2025	<b>(18,000)</b>

The Charity moved in to new offices at the start of 2024 and is providing for dilapidations over the lifetime of the lease.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 15 Designated funds - Group and Charity

Designated funds are funds earmarked by the board of Trustees for particular purposes. At the year end, the balance of designated funds were as follows:

	<b>Balance at 01-Jan-25</b>	<b>Incoming</b>	<b>Outgoing</b>	<b>Balance at 31-Dec-25</b>
Research Fund	12,405	-	(12,405)	-
Local voluntary support groups	33,235	3,804	(5,992)	31,047
	<b><u>45,640</u></b>	<b><u>3,804</u></b>	<b><u>(18,397)</u></b>	<b><u>31,047</u></b>
	<b>Balance at 01-Jan-24</b>	<b>Incoming</b>	<b>Outgoing</b>	<b>Balance at 31-Dec-24</b>
Research Fund	12,405	-	-	12,405
Local voluntary support groups	80,818	4,238	(51,821)	33,235
	<b><u>93,223</u></b>	<b><u>4,238</u></b>	<b><u>(51,821)</u></b>	<b><u>45,640</u></b>

#### Research

Funds to be used for funding medical research into coeliac disease and dermatitis herpetiformis, designated by the Board from unrestricted funds.

#### Local voluntary support groups

The collective funds held and administered by Volunteer Groups, representing their working funds.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 16 Restricted funds - Group and Charity

	Balance B/F	Incoming	Outgoing	Transfer of funds	Balance at 31-Dec-25
Research Fund	232,718	123,721	(132,577)	-	223,862
Awareness Week	7,346	31,000	(35,014)	-	3,332
Events for children with Coeliac Disease and families	5,027	-	-	-	5,027
Gluten Ataxia	-	19,500	(19,500)	-	-
Digital Meal Planner	-	9,430	-	-	9,430
Healthcare Support & Policy	-	47,492	(20,987)	-	26,505
Scotland	-	95,166	(95,166)	-	-
Local Support	-	50	(50)	-	-
	<b>245,090</b>	<b>326,360</b>	<b>(303,294)</b>	<b>-</b>	<b>268,156</b>

	Balance B/F	Incoming	Outgoing	Transfer of funds	Balance at 31-Dec-24
Research Fund	197,912	219,058	(225,550)	41,298	232,718
Daily newspaper advert for Awareness Week	1,488	-	(1,488)	-	-
Awareness Week	-	40,000	(55,241)	22,587	7,346
Membership Helpline	166	7	(173)	-	-
Pharmacy Packs	1,073	-	(1,073)	-	-
Diagnosis campaign	21,099	-	(21,099)	-	-
Events for children with Coeliac Disease and families	5,027	-	-	-	5,027
Gluten Ataxia	-	40,225	-	- 40,225	-
Sponsored Dissertations	7,500	-	(7,500)	-	-
	<b>234,265</b>	<b>299,290</b>	<b>(312,124)</b>	<b>23,660</b>	<b>245,090</b>

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Notes to the financial statements (Continued)

#### 16 Restricted funds - Group and Charity

The principal purposes for the above restricted funds were as follows:

##### **Research**

Income received to be used solely for funding medical research into coeliac disease and dermatitis herperiformis (DH).

##### **Local support**

The collective funds held and administered by Volunteer Groups.

##### **Daily newspaper advert for Awareness Week**

Donations towards an advertisement to be placed in a major national newspaper during Awareness Week to raise the profile of coeliac disease.

##### **Membership Helpline**

Funding for ongoing costs of providing the Coeliac UK Helpline.

##### **Pharmacy packs**

Donations towards production of pharmacy information packs.

##### **Gluten Ataxia**

Income to fund a project to achieve an earlier diagnosis for those with Gluten Ataxia.

##### **Events for children with CD and families**

Funds to be used by Coeliac UK for events to benefit coeliac children and their families.

##### **Diagnosis Campaign**

Funds have been granted to pay for the development of campaign materials to promote diagnosis of coeliac disease in children for a campaign in 2022 in support of ongoing activities regarding awareness and education on coeliac disease.

##### **Awareness Week**

Funds have been granted to support the Awareness week campaign of coeliac disease in support of ongoing activities regarding awareness and education on coeliac disease.

##### **Sponsored Dissertations**

Funds have been granted to support the award of grants to support students preparing dissertations relating to advancement in the research of coeliac disease, with additional hope this will encourage their ongoing and long-term engagement in coeliac disease research

##### **Digital Meal Planner**

Funds have been granted to support the digital meal planner provision for people with coeliac disease.

##### **Healthcare Support & Policy**

Funds have been granted to support the healthcare support and policy work of coeliac uk.

##### **Scotland**

Funds have been granted to support Coeliac UK's work in Scotland.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 17 Analysis of net assets between funds - Group

	Unrestricted funds 2025	Designated funds 2025	Restricted funds 2025	Total 2025
Intangible assets	126,814	-	-	126,814
Tangible assets	119,880	-	-	119,880
Investments	1,037,554	-	-	1,037,554
Net current assets less provisions for liabilities and charges	193,680	31,047	268,156	492,883
	<b><u>1,477,928</u></b>	<b><u>31,047</u></b>	<b><u>268,156</u></b>	<b><u>1,777,131</u></b>
	Unrestricted funds 2024	Designated funds 2024	Restricted funds 2024	Total 2024
Intangible assets	121,173	-	-	121,173
Tangible assets	157,966	-	-	157,966
Investments	1,019,969	-	-	1,019,969
Net current assets less provisions for liabilities and charges	325,877	45,640	245,090	616,607
	<b><u>1,624,985</u></b>	<b><u>45,640</u></b>	<b><u>245,090</u></b>	<b><u>1,915,714</u></b>

#### 18 Lease commitments - Group

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	Land and buildings		Office equipment	
	2025	2024	2025	2024
	£	£	£	£
Within one year	80,888	82,287	3,115	3,115
Between two and five years	233,676	321,149	8,675	10,636
More than five years	-	-	85	1,282
	<b><u>314,564</u></b>	<b><u>403,436</u></b>	<b><u>11,875</u></b>	<b><u>15,033</u></b>

#### 19 Voluntary help

The charity received support from 281 volunteers in 2025 (2024: 256). The benefit of their contribution is not reflected in the financial statements.

#### 20 Related party transactions

Coeliac UK holds 100% of the share capital of The Coeliac Trading Company Limited. Details of transactions in the year and balances at the year end are detailed in note 11.

There were no other related party transactions in the reporting period that require disclosure.

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

### Notes to the financial statements (Continued)

#### 21 Pension commitments

The estimated pension deficit as at 31 December 2025 is £943 (31 December 2024: £1275). This is in accordance with the most recent independent valuation performed on 30 September 2023. Under the new recovery plan, from 1 April 2023 the deficit contributions that are required from Coeliac UK are £392 a year (2024 £772) , payable in monthly instalments of £32.67. These payments do not increase.

The deficit contributions agreed between the company and scheme at the yearend date are as follows:

Year	Amount
1	438
2	438
3	109
4	-

The present value of the future provision for Coeliac UK is calculated as follows:

	<b>£</b>
Provision at the start of the period	1,275
Discount factor interest expense	52
Deficit contribution paid	(392)
Remeasurement - impact of change in assumptions	8
Remeasurements - amendments to the contribution schedule	-
Provision at end of period 31 December 2025	943

The current deficit of £943 is being paid at an immaterial amount to the charity on an annual basis, this deficit would only fall due in its entirety should the charity decide to withdraw from the scheme, the Board of Trustees currently have no such plans.

#### 22 Reconciliation of net income/(expenditure) for the reporting period (as per the SOFA)

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Net income/(expenditure) for the reporting period (as per the SOFA)	(138,582)	(435,994)
Adjustments for:		
Depreciation charges	136,782	107,588
(Gains)/losses on investments	(67,585)	(37,389)
Dividends from investments	(41,607)	(41,836)
Bank interest	(23,560)	(26,686)
(Increase)/decrease in debtors	153,345	(95,269)
Decrease/(increase) in creditors	(143,619)	96,626
Increase in Provision for Liabilities	9,000	9,000
Other Gains/Losses	-	-
Net cash provided by operating activities	<b><u>(115,826)</u></b>	<b><u>(423,960)</u></b>

# Coeliac UK

## Annual Report and Financial Statements for the year ended 31 December 2025

---

### Notes to the financial statements (Continued)

#### 23 Analysis of cash and cash equivalents

	2025 £	2024 £
Cash in hand	27	106
Notice deposits (less than 3 months)	694,522	799,440
Total cash and cash equivalents	<u>694,549</u>	<u>799,545</u>

#### Analysis of changes in net debt

	Balance at 01-Jan-25	Cash flows	Balance at 31-Dec-25
Cash	106	(79)	27
cash equivalents	799,439	(104,917)	694,522
	<u>799,545</u>	<u>(104,996)</u>	<u>694,549</u>

#### 24 Contingent Liability

There were no contingent liabilities at this time